Výsledky vyhledávání

Akademický článek

Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group

Publikováno v: Blood Cancer Journal, Vol 13, Iss 1, Pp 1-7 (2023)

Abstract Realgar-Indigo naturalis formula (RIF), an oral traditional Chinese medicine mainly containing Realgar (As4S4), is highly effective in treating adult acute promyelocytic leukemia (APL). However, the treatment efficacy and safety of RIF have

Externí odkaz: https://doaj.org/article/a27677eab83745ecac34975e1f01041a

Zobrazit plný text záznamu

Akademický článek

Prognostic significance of CNSL at diagnosis of childhood B-cell acute lymphoblastic leukemia: A report from the South China Children’s Leukemia Group

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

ObjectivesThe prognostic significance of acute lymphoblastic leukemia (ALL) patients with central nervous system leukemia (CNSL) at diagnosis is controversial. We aimed to determine the impact of CNSL at diagnosis on the clinical outcomes of childhoo

Externí odkaz: https://doaj.org/article/44744bb0eb36457e9857f1dca5e1147d

Zobrazit plný text záznamu

Akademický článek

Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol

Autor: Xin-Yu Li, Jia-Qiang Li, Xue-Qun Luo, Xue-Dong Wu, Xin Sun, Hong-Gui Xu, Chang-Gang Li, Ri-Yang Liu, Xiao-Fei Sun, Hui-Qin Chen, Yu-Deng Lin, Chi-kong LI, Jian-Pei Fang

Publikováno v: BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)

Abstract Background The prognosis of childhood acute lymphoblastic leukemia (ALL) is optimistic with a 5-year event-free survival (EFS) rate of 70–85%. However, the major causes of mortality are chemotherapy toxicity, infection and relapse. The Gua

Externí odkaz: https://doaj.org/article/598bd0c56f2e463e91357af329b8584c

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

A Nomogram for Predicting Event-Free Survival in Childhood Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

ObjectiveEven though childhood acute lymphoblastic leukemia (ALL) has an encouraging survival rate in recent years, some patients are still at risk of relapse or even death. Therefore, we aimed to construct a nomogram to predict event-free survival (

Externí odkaz: https://doaj.org/article/1181aba47a52401dbc60328a7eca4f03

Zobrazit plný text záznamu

Akademický článek

Prognostic Value and Outcome for ETV6/RUNX1-Positive Pediatric Acute Lymphoblastic Leukemia: A Report From the South China Children’s Leukemia Group

Publikováno v: Frontiers in Oncology, Vol 11 (2021)

PurposeTo analyzed the outcome of ETV6/RUNX1-positive pediatric acute B lymphoblastic leukemia (B-ALL) with the aim of identifying prognostic value.MethodA total of 2,530 pediatric patients who were diagnosed with B-ALL were classified into two group

Externí odkaz: https://doaj.org/article/348375087ff341a19f0e6f40c3406e09

Zobrazit plný text záznamu

Reduced intensity of induction does not increase the risk of relapse in childhood acute lymphoblastic leukemia - A multi-centric clinical study of GD-2008-ALL protocol

Autor: Xue-Dong Wu, Xiaofei Sun, Jian-Pei Fang, Xin Sun, Hong-Gui Xu, Chang-Gang Li, Jia-Qiang Li, Ri-Yang Liu, Chi-kong Li, Hui-Qin Chen, Yu-Deng Lin, Xin-Yu Li, Xue-Qun Luo

Background The prognosis of childhood acute lymphoblastic leukemia (ALL) is optimistic with a 5-year event-free survival (EFS) rate of 70%-85%. However, the major causes of mortality are chemotherapy toxicity, infection and relapse. The Guangdong(GD)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ffbcd5d2082595f68dee5a2ab81ad1bb
https://doi.org/10.21203/rs.3.rs-25689/v1

Zobrazit plný text záznamu

Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol

Autor: Chang-Gang Li, Xue-Dong Wu, Xue-Qun Luo, Chi-kong Li, Hui-Qin Chen, Ri-Yang Liu, Yu-Deng Lin, Xiaofei Sun, Jia-Qiang Li, Xin Sun, Hong-Gui Xu, Xin-Yu Li, Jian-Pei Fang

Publikováno v: BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)

Background The prognosis of childhood acute lymphoblastic leukemia (ALL) is optimistic with a 5-year event-free survival (EFS) rate of 70–85%. However, the major causes of mortality are chemotherapy toxicity, infection and relapse. The Guangdong (G

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c481931a74258332a9c70c5bda550321
https://pubmed.ncbi.nlm.nih.gov/33435902

Zobrazit plný text záznamu

Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study

Autor: Bin Li, Ri Yang Liu, Jian Li, Li-Bin Huang, Ke Huang, Wu Qing Wan, Xiaofei Sun, Xiaoqin Feng, Yan Lai Tang, Jie Si Luo, Zhi Yong Ke, Li Hua Yang, Guo Hua Chen, Min Cui Zheng, Hui Qin Chen, Hui Rong Mai, Ming Hua Yang, Xue Qun Luo

Publikováno v: American Journal of Hematology

Intravenous arsenic trioxide (ATO) has been adopted as the first‐line treatment for acute promyelocytic leukemia (APL). Another arsenic compound named the Realgar‐Indigo naturalis formula (RIF), an oral traditional Chinese medicine containing As4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c155007d184d1ceb007d2e0e82aef755
https://pubmed.ncbi.nlm.nih.gov/30160789

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání